Skip to main content

Table 1 Clinical characteristics of the patients

From: An objective nodal staging system for breast cancer patients undergoing neoadjuvant systemic treatment

   Development n (%) Validation n (%) p
(n = 260) (n = 132)  
Age (median, range)   46 (24–78) 46 (27–72)  
Breast Surgery Breast conserving surgery 120 (46.2) 63 (47.7) 0.768
Total mastectomy 140 (53.8) 69 (52.3)  
Axilla Surgery Sentinel lymph node biopsya 13 (5.0) 8 (6.2) 0.634
Axillary lymph node dissection 247 (95.0) 122 (93.8)  
Clinical T stage T1 3 (1.2) 4 (3.0) 0.061
T2 126 (48.5) 54 (40.9)  
T3 86 (33.1) 58 (43.9)  
T4 45 (17.3) 16 (12.1)  
AJCC Stage II 75 (28.8) 35 (26.5) 0.627
III 185 (71.2) 97 (73.5)  
Histology Ductal 237 (91.2) 121 (91.7) 0.528
Lobular 6 (2.3) 5 (3.8)  
Mixed/other 17 (6.5) 6 (4.5)  
Grade Low (I and II) 105 (40.4) 58 (43.9) 0.667
High (III) 127 (48.8) 63 (47.7)  
Unknown 28 (10.8) 11 (8.3)  
HRc status Positive 164 (63.1) 95 (72.0) 0.079
Negative 96 (36.9) 37 (28.0)  
HER2 status Positive 66 (25.4) 46 (34.8) 0.072
Negative 193 (74.2) 86 (65.2)  
Unknown 1 (0.4) 0 (0.0)  
Subtype HRc+/HER2- 131 (50.4) 69 (52.3) 0.137
HRc+/HER2+ 33 (12.7) 26 (19.7)  
HRc−/HER2+ 34 (13.1) 18 (13.6)  
HRc−/HER2- 61 (23.5) 19 (14.4)  
Unknown 1 (0.4) 0 (0.0)  
Ki-67 < 10% 133 (51.2) 72 (54.5) 0.705
≥ 10% 121 (46.5) 56 (42.4)  
Unknown 6 (2.3) 4 (3.0)  
Type of NST Anthracyclines 8 (3.1) 6 (4.5) 0.879
Anthracyclines and Taxanes 239 (91.9) 120 (90.9)  
Taxanes 10 (3.8) 5 (3.8)  
Others 3 (1.2) 1 (0.8)  
Anti-HER2 Therapy Neoadjuvant 12 (4.6) 6 (4.5) 0.968
Adjuvant 52 (19.9) 25 (18.9)  
No 196 (75.5) 101 (76.5)  
  1. AJCC American Joint Committee on Cancer, HRc hormone receptor, HER2 human epidermal growth factor receptor 2, NST neoadjuvant systemic treatment
  2. aAll sentinel lymph node procedures were performed after neoadjuvant systemic treatment